BATS:ARKG ARK Genomic Revolution ETF (ARKG) Price, Holdings, & News $25.32 +1.72 (+7.26%) As of 03:54 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsBuy This Stock About ARK Genomic Revolution ETF (BATS:ARKG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARKG alerts:Sign Up Key Stats Today's Range$24.20▼$25.2450-Day Range$23.07▼$26.5652-Week Range$17.51▼$31.16Volume4.90 million shsAverage Volume2.73 million shsMarket Capitalization$1.13 billionAssets Under Management$1.01 billionDividend YieldN/ANet Expense Ratio0.75%Aggregate RatingModerate Buy ETF Overview The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK. Read More ARK Genomic Revolution ETF ExpensesTypeARKGTheme ETFsEquity ETFsBATS ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.57%0.53%Other Expenses0.00%0.57%0.56%0.48%0.56%Total Expense0.75%0.74%0.76%0.71%0.73%Fee Waiver0.00%-0.76%-0.66%-0.46%-0.63%Net Expense0.75%0.60%0.63%0.64%0.60% Receive ARKG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARK Genomic Revolution ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address ARKG ETF News HeadlinesCathie Wood Sells Roku Stock, Doubles Down on Biotech BetsAugust 21 at 4:54 AM | msn.comCathie Wood Snaps Up $17 Million Robinhood Stake on the DipAugust 20 at 6:49 PM | uk.finance.yahoo.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 22 at 2:00 AM | InvestorPlace (Ad)Cathie Wood ‘Buys the Dip’ in Robinhood, CRISPR, and Beam Therapeutics StocksAugust 20 at 4:43 AM | msn.comWhy Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)July 25, 2025 | finance.yahoo.comARKG: April's Wash-Out Low Is Encouraging, Healthcare Still SoftJuly 25, 2025 | seekingalpha.comSee More Headlines ARKG ETF - Frequently Asked Questions How have ARKG shares performed this year? ARK Genomic Revolution ETF's stock was trading at $23.5450 on January 1st, 2025. Since then, ARKG stock has increased by 7.3% and is now trading at $25.2540. Who are ARK Genomic Revolution ETF's major shareholders? Top institutional investors of ARK Genomic Revolution ETF include JPMorgan Chase & Co. (9.74%), BNP Paribas Financial Markets (5.91%), Jane Street Group LLC and Kingstone Capital Partners Texas LLC (0.35%). How do I buy shares of ARK Genomic Revolution ETF? Shares of ARKG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARK Genomic Revolution ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARK Genomic Revolution ETF investors own include Invesco QQQ (QQQ), ARK Innovation ETF (ARKK), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), AbbVie (ABBV) and PayPal (PYPL). Fund Details IssuerARK Fund NameARK Genomic Revolution ETF Tax ClassificationRegulated Investment Company Stock ExchangeBATSCurrent SymbolBATS:ARKG Inception Date10/31/2014 Fund ManagerCatherine Wood WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkN/A CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings39 Fund Statistics Assets Under Management$1.01 billion Average Daily Volume$2.38 million Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorARK Investment Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorForeside Fund Services, LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume2,062 Put Options961 Call Options1,101 Miscellaneous Outstanding Shares44,700,000Beta1.62 Creation Unit50,000 Creation Fee$500.00 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report Top 10 ARKG HoldingsTempus AI (NASDAQ:TEM)Holding Weight: 11.21%CRISPR Therapeutics (NASDAQ:CRSP)Holding Weight: 9.81%Twist Bioscience (NASDAQ:TWST)Holding Weight: 5.86%Recursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 5.72%Guardant Health (NASDAQ:GH)Holding Weight: 4.69%Natera (NASDAQ:NTRA)Holding Weight: 4.49%10x Genomics (NASDAQ:TXG)Holding Weight: 4.25%Adaptive Biotechnologies (NASDAQ:ADPT)Holding Weight: 4.00%Schrodinger (NASDAQ:SDGR)Holding Weight: 3.65%Illumina (NASDAQ:ILMN)Holding Weight: 3.64%Full Holdings DetailsARKG Sector ExposureARKG Industry Exposure This page (BATS:ARKG) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARK Genomic Revolution ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share ARK Genomic Revolution ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access